CIP
BBIO icon

Chartwell Investment Partners’s BridgeBio Pharma BBIO Stock Holding History

Chartwell Investment Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,276
Closed -$763K – 428
2021
Q3 		$763K Hold
16,276
– – 0.02% 393
2021
Q2 		$992K Buy
16,276
+4,931
+43% +$282K 0.03% 378
2021
Q1 		$699K Buy
+11,345
New +$742K 0.02% 382

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chartwell Investment Partners's BBIO Position: Q4 2021 in Review

Chartwell Investment Partners sold out of BridgeBio Pharma (BBIO) in Q4 2021, closing a stake of 16,276 shares — an estimated $763K sold.

Chartwell Investment Partners first reported a position in BBIO in Q1 2021 and held it in 3 quarters. The position peaked at $992K in Q2 2021. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

  • Chartwell Investment Partners reported no remaining BridgeBio Pharma position as of Q4 2021 after selling out during the quarter.
  • Chartwell Investment Partners sold 16,276 BridgeBio Pharma shares in Q4 2021, an estimated $763K.
  • Chartwell Investment Partners first reported a position in BridgeBio Pharma in Q1 2021 and held it in 3 quarters.
  • Chartwell Investment Partners's BridgeBio Pharma position peaked at $992K in Q2 2021.
  • 195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Chartwell Investment Partners's 13F filing for Q4 2021, filed 15 Feb 2022.